Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
This study is testing a new way to treat high-risk Mantle Cell Lymphoma (MCL), a type of blood cancer. Researchers want to see if adding a medication called glofitamab after an initial treatment helps control the cancer more effectively.
This study is for adults with high-risk MCL who have not been treated for their cancer before. You must have measurable tumors to participate, and there are specific health and safety requirements your doctor will review with you.
Participants will receive a combination of medications designed to block cancer growth and help the immune system fight the disease. You will be closely monitored by a medical team throughout the process to track how your body responds to the treatment.
The study is currently recruiting new participants and is located in Houston, Texas. You should talk to your oncologist to see if this trial might be a good fit for your specific health needs.
- 1Tests a combination of three different cancer-fighting medications.
- 2Specifically focuses on patients with high-risk Mantle Cell Lymphoma.
- 3Requires regular check-ups to monitor safety and how well the treatment is working.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.